Equities research analysts expect Opko Health Inc. (NASDAQ:OPK) to announce ($0.07) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Opko Health’s earnings, with estimates ranging from ($0.10) to ($0.03). Opko Health reported earnings of ($0.08) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 12.5%. The company is expected to report its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Opko Health will report full year earnings of ($0.20) per share for the current fiscal year, with EPS estimates ranging from ($0.33) to ($0.06). For the next year, analysts forecast that the company will post earnings of ($0.06) per share, with EPS estimates ranging from ($0.21) to $0.10. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Opko Health.
Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The company had revenue of $221.90 million for the quarter, compared to analyst estimates of $242.05 million. Opko Health had a negative net margin of 15.46% and a negative return on equity of 7.69%.
Several analysts recently commented on the stock. Zacks Investment Research lowered shares of Opko Health from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, Barrington Research restated a “buy” rating and set a $5.00 price target on shares of Opko Health in a research report on Thursday, February 28th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Opko Health currently has a consensus rating of “Buy” and a consensus price target of $9.67.
OPK stock traded down $0.01 during midday trading on Tuesday, hitting $2.40. 6,731,012 shares of the stock traded hands, compared to its average volume of 3,690,665. The firm has a market cap of $1.48 billion, a PE ratio of -9.60 and a beta of 1.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.96 and a current ratio of 1.10. Opko Health has a 1-year low of $2.34 and a 1-year high of $6.40.
In related news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the firm’s stock in a transaction on Thursday, February 28th. The shares were acquired at an average cost of $2.48 per share, with a total value of $496,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $7,610,998.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Vice Chairman Jane Ph D. Hsiao acquired 10,000 shares of the firm’s stock in a transaction on Thursday, January 31st. The shares were bought at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the acquisition, the insider now owns 24,455,147 shares of the company’s stock, valued at $194,662,970.12. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 798,000 shares of company stock worth $2,032,580. Insiders own 42.74% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Diversified Trust Co purchased a new position in Opko Health during the fourth quarter valued at $30,000. FDx Advisors Inc. purchased a new position in Opko Health during the fourth quarter valued at $33,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Opko Health in the first quarter worth about $39,000. Meeder Asset Management Inc. lifted its stake in shares of Opko Health by 58.7% in the first quarter. Meeder Asset Management Inc. now owns 13,102 shares of the biotechnology company’s stock worth $35,000 after buying an additional 4,846 shares in the last quarter. Finally, Douglas Lane & Associates LLC purchased a new position in shares of Opko Health in the fourth quarter worth about $42,000. 23.10% of the stock is currently owned by institutional investors and hedge funds.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Featured Story: What is the float in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.